European CHMP recommends approval of alpelisib (Piqray) for treatment of locally advanced or metastatic breast cancer with PIK3CA mutation

Alpelisib, a α-specific class-I phosphatidylinositol-3-kinase (PI3Kα) inhibitor which inhibits the phosphorylation of PI3K downstream targets, including AKT, which are involved in cellular proliferation. Benefits include its ability to improve progression-free survival.


European Medicines Agency